Personalized 6-month program to reduce frailty around bladder or kidney cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Older adults with bladder or kidney cancer who are scheduled for surgical treatment will be offered a tailored 6-month program delivered partly before and after surgery. The program combines adapted physical activity sessions, therapeutic education workshops, and systematic referral to the hospital's DAPAP rehabilitation service. Participation is limited to patients without severe cognitive impairment or contraindications to exercise, and who have not already had surgery or private prehabilitation. Outcomes will focus on changes in physical conditioning, frailty markers, postoperative complications, and nutritional status over the intervention period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of bladder or kidney cancer
* Surgical treatment
* No severe cognitive impairment preventing understanding of the protocol
* Affiliated or entitled to a social security scheme
* Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study

Exclusion Criteria:

* Surgery already done
* Significant co-morbidities that contraindicate physical activity: associated cardiac pathologies, respiratory pathologies, disabling joint pathologies, etc.
* Deprived of liberty or under guardianship
* Benefiting from a prehabilitation prescription with a private physiotherapist.

Where it's running

• Chu Saint-Etienne
  Saint-Etienne, France Recruiting
• Hôpital privé de la Loire
  Saint-Etienne, France Not yet recruiting

Study contacts

• Principal investigator: David HUPIN, MD — CHU de Saint Etienne
• Study coordinator: Evolène FAYOLLE, student
• Email: evolene.fayolle@chu-st-etienne.fr
• Phone: (0)4 77 12 78 35

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Irrigation Fluid Absorption and Perioperative cfDNA Changes in TURBT for Bladder Cancer

  This study tests whether the amount of irrigation fluid absorbed during TURBT is linked to changes in tumor DNA circulating in the blood in patients with bladder cancer.

  Recruiting Lanzhou University Second Hospital · Lanzhou, Gansu · NCT07589413

• TARA-002 vs chemotherapy for high-grade non-muscle invasive bladder cancer in adults not previously treated with BCG

  A phase 3 study tests whether TARA-002 can help adults with high-grade non-muscle invasive bladder cancer who haven’t had BCG, comparing it to standard intravesical chemotherapy.

  Recruiting at 11 sites Phase 3 Protara Therapeutics · Queen Creek, Arizona and 10 other locations · NCT07480356

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.